Collateral for a security interest recorded Dec 28, 2023 (SWK Funding LLC).
Term ended Apr 28, 2024 · High confidence
20-year base term ends Oct 6, 2029
Held by Journey Medical Corporation
Filed Jul 18, 2011 as application 13/123,213 · Granted Aug 27, 2013
Base term, 20 years from filing · capped by a resolved terminal disclaimer
Today
Term ended Apr 28, 2024
2009
2029
Clock starts
Oct 6, 2009
Oct 6, 2009
Term ended
Apr 28, 2024
Apr 28, 2024
Granted
Aug 27, 2013
Aug 27, 2013
base term
after the term ends
fee events
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 8,900,553.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
11
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 6, 2009, when application PCT/IB2009/007184, the earliest non-provisional in its chain, was filed (this one was filed Jul 18, 2011) | Oct 6, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,900,553) | capped to Apr 28, 2024 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Apr 28, 2024 | High confidence |
Partial family
| Application PCT/IB2008/003932 | PCT application no patent term | no patent term |
| Application PCT/IB2008/003939 | PCT application no patent term | no patent term |
| Application PCT/IB2009/007184 | PCT application no patent term | no patent term |
| US 8,343,945 | In force Dec 2028 | Dec 2028 |
| US 8,900,553 | Lapsed on the fee record Dec 2022 | Dec 2022 |
| US 8,518,376 | this patent Apr 2024 | Apr 2024 |
| US 9,161,916 | In force Dec 2028 | Dec 2028 |
| US 9,795,564 | In force Dec 2028 | Dec 2028 |
8 of 11 applications in this family shown, earliest filings first. Partial: 4 of the 11 have no file history here, so a row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 18, 2011 Reel 26606, frame 188 | Tamarkin, Dov; Schuz, David; Hazot, Yohan; Gazal, Elana | Foamix Ltd. | Assignment of Assignor's Interest |
| Jul 30, 2014 Reel 33445, frame 249 | Foamix Ltd. | Foamix Pharmaceuticals Ltd. | Change of Name |
| Jul 30, 2019 Reel 49912, frame 45 | Foamix Pharmaceuticals Ltd. | Perceptive Credit Holdings II, LP | Patent Security Agreement |
| Nov 4, 2020 Reel 54306, frame 387 | Foamix Pharmaceuticals Ltd. | Vyne Pharmaceuticals Ltd. | Change of Name |
| Feb 4, 2021 Reel 55215, frame 298 | Vyne Pharmaceuticals Ltd. | Vyne Therapeutics Inc. | Assignment of Assignor's Interest |
| Feb 17, 2021 Reel 55326, frame 9 | Vyne Therapeutics Inc. | Perceptive Credit Holdings II, LP | Patent Security Agreement |
| Sep 20, 2021 Reel 57544, frame 138 | Perceptive Credit Holdings II, LP | Vyne Pharmaceuticals Ltd. (F/K/A Foamix Pharmaceuticals Ltd.) | Release of Security Interest |
| Sep 20, 2021 Reel 57544, frame 708 | Perceptive Credit Holdings II, LP | Vyne Therapeutics Inc. (F/K/A Menlo Therapeutics Inc. and Successor-in-Interest to Vyne Pharmaceuticals Ltd., F/K/A Foamix Pharmaceuticals Ltd.) | Release of Security Interest |
| Dec 22, 2021 Reel 58463, frame 167 | Vyne Therapeutics Inc. | Vyne Pharmaceuticals Inc. | Assignment of Assignor's Interest |
| Feb 1, 2022 Reel 58925, frame 568 | Vyne Therapeutics Inc.; Vyne Pharmaceuticals Inc. | Journey Medical Corporation | Assignment of Assignor's Interest |
| Dec 28, 2023 Reel 66157, frame 79 | Journey Medical Corporation; JG Pharma, Inc. | SWK Funding LLC | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 8,900,553.
Citations
217
later US patents cite this one
That is top 5% of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.